Current Research and Use of Mesenchymal Stem Cells in the Therapy of Autoimmune Diseases

2019 ◽  
Vol 14 (7) ◽  
pp. 579-582 ◽  
Author(s):  
Youdong Chen ◽  
Qian Yu ◽  
Yifan Hu ◽  
Yuling Shi

: Mesenchymal Stem Cells (MSCs) represent a heterogeneous group of self-renewal, multipotent non-hematopoietic stem cells, which display profound immunomodulatory functions and promising therapeutic effects. Autoimmune diseases, which result from an aberrant immune response to selfantigens, can be detrimental to nearly all body tissues. With the advance in developing a novel treatment, including biological agents, it is still impossible to cure autoimmune disorders. Recent studies demonstrate the remarkable therapeutic effectiveness of MSCs towards a wide array of autoimmune diseases. In this review, the immunomodulatory influence of MSCs over immune cells and the application of MSCs transplantation in treating autoimmune diseases are highlighted.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2335-2335
Author(s):  
Iekuni Oh ◽  
Akira Miyazato ◽  
Hiroyuki Mano ◽  
Tadashi Nagai ◽  
Kazuo Muroi ◽  
...  

Abstract Mesenchymal stem cells (MSCs) account for a very small population in bone marrow stroma as a non-hematopoietic component with multipotency of differentiation into adipocytes, osteocytes and chondrocytes. MSC-derived cells are known to have hematopoiesis-supporting and immunomodulatory abilities. Although clinical applications of MSCs have already been conducted for the suppression of graft versus host disease in allogeneic stem cell transplantation and for tissue regeneration, underlying mechanisms of the biological events are still obscure. Previously, we established a differentiation model of MSCs using a mouse embryo fibroblast cell line, C3H10T1/2 (10T1/2) (Nishikawa M et al: Blood81:1184–1192, 1993). Preadipocyte (A54) and myoblast (M1601) cell lines were cloned by treatment with 5-azacytidine. A54 cells and M1601 cells can terminally differentiate into adipocytes and myotubes, respectively, under appropriate conditions, while parent 10T1/2 cells remain undifferentiated. Moreover, A54 cells show a higher ability to support hematopoiesis compared with the other cell lines. In this study, we analyzed gene expression profiles of the three cell lines by using DNA microarray and real-time PCR to investigate molecular mechanisms for maintaining immaturity of parent 10T1/2 cells. In A54 cells, 202 genes were up-regulated, including those encoding critical factors for hematopoiesis such as SCF, Angiopoietin-1, and SDF-1 as well as genes known to be involved in adipocyte differentiation such as C/EBPα, C/EBPδ and PPAR-γ genes. These data are consistent with the hematopoiesis-supporting ability of A54 cells. During adipocyte differentiation, SCF and SDF-1 expression levels decreased in A54 cells while C/EBPα expression showed a steady level. Recently, osteoblasts have been reported to play crucial roles in “niche” for self-renewal of hematopoietic stem cells. Our results also implicate that precursor cells of non-hematopoietic components may have important roles for hematopoiesis in bone marrow. Meanwhile, in parent 10T1/2 cells, 105 genes were up-regulated, including CD90, Dlk, Wnt5α and many functionally unknown genes. Although C/EBPα expression was induced in 10T1/2 cells without differentiation under the adipocyte differentiation conditions, CD90 expression decreased, Dlk showed a steady level and Wnt5α was up-regulated. Assuming that some regulatory mechanisms are needed to keep an immature state of parent 10T1/2 cells even under the differentiation-inducible conditions, we performed following experiments. First, enforced Dlk expression in A54 cells did not inhibit terminal differentiation to adipocytes under the differentiation conditions. Second, when we cultured A54 cells in the conditioned media of parent 10T1/2 cells under the differentiation-inducible conditions, adipocyte differentiation was inhibited, suggesting that 10T1/2 cells produce some soluble molecules that can inhibit adipocyte differentiation. Since Wnt family is known to be involved in the regulation of self-renewal of several stem cells, Wnt5α may be one candidate for maintenance of “stemness” of MSCs. Taken together, the data of 10T1/2 cells suggest that MSCs can self-regulate their differentiation in the bone marrow stromal system. This concept may be important to investigate the fatty change of bone marrow in aging and in aplastic anemia.


2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Lukun Zhou ◽  
Shuang Liu ◽  
Zhao Wang ◽  
Jianfeng Yao ◽  
Wenbin Cao ◽  
...  

Abstract Background Liver injury associated with acute graft-versus-host disease (aGVHD) is a frequent and severe complication of hematopoietic stem cell transplantation and remains a major cause of transplant-related mortality. Bone marrow-derived mesenchymal stem cells (BM-MSCs) has been proposed as a potential therapeutic approach for aGVHD. However, the therapeutic effects are not always achieved. In this study, we genetically engineered C57BL/6 mouse BM-MSCs with AKT1 gene and tested whether AKT1-MSCs was superior to control MSCs (Null-MSCs) for cell therapy of liver aGVHD. Results In vitro apoptosis analyses showed that, under both routine culture condition and high concentration interferon-γ (IFN-γ) (100ng/mL) stimulation condition, AKT1-MSCs had a survival (anti-apoptotic) advantage compared to Null-MSCs. In vivo imaging showed that AKT1-MSCs had better homing capacity and longer persistence in injured liver compared to Null-MSCs. Most importantly, AKT1-MSCs demonstrated an enhanced immunomodulatory function by releasing more immunosuppressive cytokines, such as IL-10. Adoptive transfer of AKT1-MSCs mitigated the histopathological abnormalities of concanavalin A(ConA)-induced liver injury along with significantly lowered serum levels of ALT and AST. The attenuation of liver injury correlated with the decrease of TNF-α and IFN-γ both in liver tissue and in the serum. Conclusions In summary, BM-MSCs genetically modified with AKT1 has a survival advantage and an enhanced immunomodulatory function both in vitro and in vivo and thus demonstrates the therapeutic potential for prevention and amelioration of liver GVHD and other immunity-associated liver injuries.


Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 736
Author(s):  
Giovanni Ferrara ◽  
Federico Ivaldi ◽  
Gianluigi Mancardi ◽  
Nicole Kerlero de Rosbo ◽  
Antonio Uccelli

Multiple sclerosis (MS) is a neurological disorder characterized by an autoimmune response, demyelinating plaques and axonal damage. Intense immunosuppression (II) followed by autologous hematopoietic stem cell transplantation has been proposed as a treatment in severe forms of MS. We have used murine relapsing-remitting (RR) experimental autoimmune encephalomyelitis (RR-EAE) to evaluate the transplantation of syngeneic bone marrow cells (BMC) after II, in combination with mesenchymal stem cells (MSCs) as a new therapeutic adjunct capable of improving immune reconstitution. In EAE-affected mice treated with BMC alone, we observed a drastic reduction in the clinical course only during the early RR phase of the disease. There was no difference in the RR-EAE clinical course between mice treated with BMC alone and co-transplanted mice. To analyze the immune reconstitution, we quantified the circulating immune cells in naïve and RR-EAE-affected mice after II, with BMC alone or in combination with MSC. Although II resulted in reduced numbers of circulating immune cells, reconstitution did not differ in co-transplanted mice. During the early phase of the disease, IL-4 was significantly elevated in co-transplanted mice, as compared to those treated with BMC alone. These data suggest that BMC transplantation after II transiently ameliorates the clinical symptoms of RR-EAE, but that co-transplantation with MSC has no synergistic effect.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 505-505
Author(s):  
Sandra Pinho ◽  
Julie Lacombe ◽  
Maher Hanoun ◽  
Ingmar Bruns ◽  
Yuya Kunisaki ◽  
...  

Abstract Abstract 505 Few markers have thus far been identified on native mesenchymal stem cells (MSCs), both in the mouse and human systems. Most markers cited in the literature are indeed based on expression analyses on heterogeneous cultured cell populations, which may not have self-renewal properties if rigorously tested by transplantation assays. Previous studies using Nestin (Nes)-Gfp transgenic mice showed that Nes-GFP+ cells are self-renewing MSCs, a major constituent of the hematopoietic stem cell (HSC) niche in the bone marrow (BM) (Nature 2010; 466:829). However, the cytoplasmic location of Nestin precludes prospective live cell isolation outside of the transgenic mice. Hence, finding a combination of surface markers labeling Nestin+ cells in situ would be valuable to isolate bona fide MSCs and characterize niche cells. Screening analyses toward this end revealed that PDGFRα and CD51 expression among CD45− Ter119− CD31− BM stromal cells comprised a large fraction (∼60%) of Nes-GFP+ cells. Upon gating first on PDGFRα+ and CD51+, double-positive cells were also highly enriched in Nes-GFP+ cells (∼75%), and represented a rare fraction (∼2%) of the stromal population. Endogenous Nestin expression was also enriched in PDGFRα+ CD51+ cells, compared to single-positive or double-negative stromal cells (control subsets). Cell sorting of BM PDGFRα+ CD51+ and control subsets revealed that PDGFRα+ CD51+ significantly enriched (> 10-fold, p<0.05) for colony forming unit-fibroblastic (CFU-F) and multipotent clonal mesenspheres (> 7-fold, p<0.01) that differentiate robustly along the osteoblastic, chondrocytic and adipocytic lineages. To test in vivo self-renewal capacity, clonal spheres or polyclonal freshly sorted PDGFRα+ CD51+ cells and control subsets were transplanted into recipient mice by different approaches (renal capsule implants, collagen and/or HA/TCP carrier grafts). After 2 months, secondary sphere formation assays and histological analyses revealed the in vivo self-renewal and heterotopic BM niche regeneration capacity of PDGFRα+ CD51+ cells, but not the control subsets. In addition, the PDGFRα+ CD51+ fraction of Nestin+ cells was markedly enriched in major HSC regulatory genes (Cxcl12, Vcam1, Angpt1, Opn and Scf), supporting the notion that niche activity co-segregates with MSC activity in the BM. Next, we investigated whether PDGFRα+ CD51+ cells also labeled putative Nestin+ MSCs in the human BM. To this end, we analyzed the fetal human BM (13–19 gw), a period during which hematopoietic activity is nascent. At this stage, we found that PDGFRα+ CD51+ cells comprised ∼3% of stromal cells, contained most of the CFU-F activity (6.3 ± 0.8 CFU-Fs/102 cells) in the BM, and also expressed Nestin and HSC regulatory factors. PDGFRα+ CD51+ cells could also form mesenspheres that can self-renew in vivo after heterotopic transplantation. Furthermore, we found that human BM PDGFRα+ CD51+ cells represented a subset of CD146+ cells previously suggested to mark human MSCs (Cell 2007; 131:324), as ∼30% of the CD146high cells also expressed PDGFRα and CD51, and ∼65% of PDGFRα+ CD51+ cells were CD146high. To evaluate functionally the HSC niche properties of human PDGFRα+ CD51+ cells, we set up a co-culture system of human BM CD34+ cells with PDGFRα+ CD51+ mesenspheres. We found that mesenspheres were capable of expanding the number of human CD45+ Lin− CD38− CD34+ CD90+ CD49f+ cells (hHSCs) by 11-fold (p<0.05) compared to input (day 0). In addition, hHSC expansion was 2-fold greater (p<0.05) using mesenspheres compared to serum-free media alone with hematopoietic growth factors (SCF, TPO, Flt3L). Recent studies have suggested that SCF production in the BM niche is derived from perivascular and endothelial cells distinct from Nestin+ cells (Nature 2012; 481:457), although Nestin+ MSCs express high levels of SCF (Nature 2010; 466:829). Immunofluorescence analyses of human PDGFRα+ CD51+ mesenspheres showed that all cells forming the sphere uniformly expressed both Nestin and SCF. Moreover, in the absence of SCF from the media, PDGFRα+ CD51+ mesenspheres rescued hHSCs expansion, yielding a 46- and 5-fold (p<0.001) expansion, as compared to control media alone and input, respectively. These results thus indicate that the HSC niche is conserved between the murine and human species and suggest that highly purified non-adherent cultures of niche cells may represent a useful novel technology to expand hHSCs in vitro. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1396-1396
Author(s):  
Patrick Wuchter ◽  
Rainer Saffrich ◽  
Beate Straub ◽  
Judit Boda-Heggemann ◽  
Katrin Miesala ◽  
...  

Abstract The interaction between hematopoietic stem cells and their niche is essential for the balance between self-renewal and differentiation. We previously demonstrated that intercellular connections in mesenchymal stem cells (MSC) are realized by occasional gap junctions and frequent adherens junctions, comprising specific cadherin-catenin-complexes. Using MSC-feeder-layer as a surrogate model for the hematopoietic stem cell (HSC) niche, we have analyzed the intercellular junctional complexes between HSC and MSC. MSC were obtained from bone marrow aspirates from healthy voluntary donors. HSC were isolated from umbilical cord blood. Using advanced confocal laser scanning in combination with deconvolution and volume rendering software, we were able to produce 3D-images of intercellular junctions between HSC and MSC. We used a panel of antibodies specific for various components of tight, gap and adherens junctions. Additionally, we compared the data to human and bovine bone marrow tissue in situ. We could show that intercellular connections between HSC and MSC are mainly realized by podia formation of the HSC linking to the adjacent MSC. These podia vary greatly in length and shape (uropodia, filopodia). Along these podia and especially at the contact zone to the MSC, we have identified the cytoplasmic plaque proteins alpha- and beta-catenin and protein p120ctn, as well as the transmembrane glycoprotein N-cadherin. This study provided solid evidence for the direct and intimate cellular interaction of HSCs with their niche. Direct cell contact represents a key factor for the regulation of self-renewal versus differentiation. The examination of the specific function of catenins, p120ctn and N-cadherin in this process is concurrently underway.


2013 ◽  
Vol 305 (10) ◽  
pp. E1185-E1194 ◽  
Author(s):  
Dimitrios Agas ◽  
Luigi Marchetti ◽  
Melania Capitani ◽  
Maria Giovanna Sabbieti

The microenvironment of bone marrow, an extraordinarily heterogeneous and dynamic system, is populated by bone and immune cells, and its functional dimension has been at the forefront of recent studies in the field of osteoimmunology. The interaction of both marrow niches supports self-renewal, differentiation, and homing of the hematopoietic stem cells and provides the essential regulatory molecules for osteoblast and osteoclast homeostasis. Impaired signaling within the niches results in a pathological tableau and enhances disease, including osteoporosis and arthritis, or the rejection of hematopoietic stem cell transplants. Discovering the anabolic players that control these mechanisms has become warranted. In this review, we focus on parathyroid hormone (PTH) and prostaglandins (PGs), potent molecular mediators, both of which carry out a multitude of functions, particularly in bone lining cells and T cells. These two regulators proved to be promising therapeutic agents when strictly clinical protocols on dose treatments were applied.


Sign in / Sign up

Export Citation Format

Share Document